Transcatheter Valve Repair System for MR and TR Patients Enables Precise Navigation and Implant Placement – Critical Care

mage: PASCAL Precision transcatheter mitral and tricuspid valve repair system received CE mark (Photo courtesy of Edwards Lifesciences)

A new transcatheter valve repair system for the treatment of mitral and tricuspid regurgitation (MR and TR) is designed to enable precise navigation and implant placement.

The PASCAL Precision Transcatheter Valve Repair System from Edwards Lifesciences (Newbury, Berkshire, UK) is used in the treatment of patients with MR and RT, via a single delivery system. The PASCAL Precision System includes the PASCAL and PASCAL Ace implants, which provide independent gripping, atraumatic clasp and closure, and implant versatility, including the ability to lengthen and navigate complex anatomy.

The PASCAL platform is designed for predictable capture, positioning and release in MR patients. The PASCAL Ace implant expands treatment options, allowing doctors to tailor the procedure to their needs. PASCAL Ace offers a narrow profile designed to improve ease of subvalvular navigation. The PASCAL Ace implant is designed for even difficult TRs, instilling the confidence to help more patients. PASCAL Ace offers a narrow implant profile designed to improve ease of subvalvular navigation.

Designed to enhance the experience with the PASCAL Platform, the PASCAL Stabilizer Rail System comes with multiple stabilizers to advance, retract, and clamp catheters. Attach the stabilizers to allow stable, incremental movements and fine adjustments. Additionally, improvements in ease of use help reduce unintended catheter movement throughout the procedure. The PASCAL Precision Transcatheter Valve Repair System has been CE marked for the treatment of MR and TR. The PASCAL Precision System is one of multiple transcatheter repair or replacement therapies being developed by Edwards and designed to treat mitral and tricuspid valve disease.

“The delivery of the PASCAL Precision System to clinicians in Europe marks another important milestone in our partnership with physicians who treat a large population of patients with mitral and tricuspid valve disease,” said Bernard J. Zovighian, vice president of ‘Edwards, mitral and tricuspid transcatheter. therapies. “Edwards has a long history of innovation, and the significant advancements of the PASCAL Precision System are designed to improve clinicians’ ability to deliver positive outcomes for patients with both MR and TR.”